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Abstract
The ability to chemically modify monoclonal antibodies with the attachment of specific functional 
groups has opened up an enormous range of possibilities for the targeted treatment and diagnosis 
of cancer in the clinic. As the number of such antibody-based drug candidates has increased, so 
too has the need for more stringent and robust preclinical evaluation of their in vivo performance 
to maximize the likelihood that time, research effort, and money are only spent developing the 
most effective and promising candidate molecules for translation to the clinic. Concurrent with the 
development of antibody-drug conjugate (ADC) technology, several recent advances in preclinical 
research stand to greatly increase the experimental rigor by which promising candidate molecules 
can be evaluated. These include advances in preclinical tumor modeling with the development 
of patient-derived tumor organoid models that far better recapitulate many aspects of the human 
disease than conventional subcutaneous xenograft models. Such models are amenable to genetic 
manipulation, which will greatly improve our understanding of the relationship between ADC and 
antigen and stringently evaluate mechanisms of therapeutic response. Finally, tumor development 
is often not visible in these in vivo models. We discuss how the application of several preclinical 
molecular imaging techniques will greatly enhance the quality of experimental data, enabling 
quantitative pre- and post-treatment tumor measurements or the precise assessment of ADCs as 
effective diagnostics. In our opinion, when taken together, these advances in preclinical cancer 
research will greatly improve the identification of effective candidate ADC molecules with the 
best chance of clinical translation and cancer patient benefit.
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INTRODUCTION
In recent years, monoclonal antibodies have become a hugely promising class of anti-cancer 
therapeutic molecules, given their high affinity and precise specificity for any number of 
tumor-specific target antigens. As an effective anti-cancer treatment, antibodies have been 
used to directly and specifically block cell surface receptor signaling (e.g., trastuzumab 
and Her2 receptor-positive breast cancer[1]). Of broader appeal, however, antibodies can 
be readily modified to carry a variety of treatment or imaging payloads and target 
them to practically any tumor-specific cell surface antigen. This effectively concentrates 
the antibody-drug conjugate (ADC) payload to sites of tumor development, significantly 
reducing possible treatment-related cytotoxicity in other organs or improving the ability to 
non-invasively image tumors above background noise[2].
The current development pipeline used to translate any promising cancer agent from the 
bench to the bedside is both high risk and prohibitively expensive in terms of both financial 
and human cost. The overall percent failure rate of taking any new molecule into the clinic 
has been reported to exceed 95%[3]. The average total development cost to FDA approval 
has recently been quoted at 2.8 billion USD[4]. Recent analysis has suggested that poorly 
predictive preclinical assays and models are a key contributing factor to this multifaceted 
problem[5]. In addition to the possible misunderstanding of mechanisms of targeting and 
therapeutic effect, misleading preclinical data also mean that critical “go, not go” decisions 
are not made until late in the drug development process after considerable research dollars 
have been spent and people have been enrolled on clinical trials with a weak premise.
As with the clinical development of any anti-cancer agent, certain aspects of ADC 
performance must first be rigorously evaluated in an experimental preclinical setting. At 
a minimum, in addition to showing safety, the target tumor antigen should be identified and 
then rigorously tested to show that in vivo accumulation of the ADC is antigen-specific 
and not the result of off-target interactions or leaky tumor vasculature and the EPR effect 
(enhanced perfusion and retention)[6]. Given that most ADCs in clinical development 
recognize and bind to human antigens, IHC staining of frozen human tissue microarrays 
will most likely be preferable over in vivo mouse models to predict where appreciable 
levels of the ADC may accumulate in the human body other than tumor sites. However, 
the relationship between ADC and target antigen in the context of whole-body physiology 
and measurements of therapeutic effect and ADC biodistribution can now be interrogated to 
much higher experimental standards.
We present here several recent advances in preclinical research that stand to significantly 
raise the rigor by which candidate ADC molecules and anti-cancer drugs can be assessed 
prior to clinical application. These include the ability to efficiently establish more 
representative in vitro and in vivo tumor models from patient-derived material (matching 
normal, tumor, and metastatic tumor organoid cell lines), the ability to use CRISPR or 
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inducible transgene technology to specifically manipulate the expression of antigen, and 
advances in non-invasive imaging that allow dynamic tracking of the ADC molecule 
or resulting treatment effects. Essentially, these advances greatly improve the quality of 
experimental control, such that the comparisons of ADC accumulation or therapeutic 
efficacy can be readily made between matched pairs of normal and tumor cells or between 
matched tumors that only differ in antigen expression. Imaging further permits many of 
these effects to be seen in the same individual subject dynamically over time, reducing 
the need for large experimental cohorts. Imaging also enables the standardization of ADC 
administration based on measured and not assumed tumor parameters, greatly improving the 
quality of data.
ADVANCES IN PRECLINICAL CANCER MODELS
The past decade has been transformative for tissue culture technology of patient-derived 
tumors. Until recently, only a limited number of immortalized 2D cancer cell lines was 
available to test the preclinical performance of an ADC using xenograft mouse models. Such 
models remain popular today as they are relatively quick and easy to develop. The cell lines 
are widely distributed among the research community, and some have been the focus of 
extensive genomic and gene expression characterization[7]. However, such cancer models 
also have significant deficiencies, can be prone to genetic drift over time, and their ability to 
accurately model human disease and ultimately predict the clinical performance of candidate 
therapeutics is questionable. The failure rate of establishing an immortalized tumor cell line 
in culture by traditional means is extremely high. Human tumors did not evolve to grow 
on tissue culture plastic as a 2D monolayer; thus, it is questionable how representative 
the low frequency of successfully established cultures are of the original tumor. Further, 
although subcutaneous engraftment of such cells in vivo is very routine (quick to establish 
and tumor development is externally visible), such models fail to recapitulate the tumor 
microenvironment that matches their native tissue of origin.
The advent of patient-derived organoid (PDO) cell cultures has set new biologically relevant 
standards that overcome many limitations of conventional 2D xenograft cell lines[8]. Tumor 
samples received fresh from the operating theatre are processed and plated out in vitro in 
a mixture of growth factors and basement membrane extract such as Matrigel (a viscous 
matrix resembling a decellularized tissue microenvironment) to provide more natural growth 
conditions for the cells. As a result, PDOs grown in three dimensions in vitro retain 
cell polarity and some semblance of structure that can provide biologically relevant cues 
[Figure 1]. The efficiency and general applicability to various tumor types also far surpass 
that of traditional 2D methods. The success rate of establishing a PDO culture can be 
as high as 75% for tumors from a wide range of epithelial organs. Once established, 
they can be propagated in vitro with relative ease in defined culture media for extended 
periods of time. Analyses suggest that organoid cultures are relatively stable genetically for 
many passages[9,10], which opens up a host of research possibilities regarding their genetic 
modification and experimental possibilities, as discussed in Sections ii and iii. Another 
ground-breaking feature of this approach is that it is possible to establish organoid cultures 
from matching normal, tumor, and metastatic tissue from the same individual. This is of 
crucial experimental importance given the outbred nature and diverse genetic background 
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of the human population. Moreover, organoids derived from sequential specimens from 
the same patient have been shown to recapitulate identical sensitivities and resistance to 
treatment, as observed in the clinic[11].
The Human Cancer Model Initiative (an NIH/NCI-funded project[12]) was established 
as a novel resource to give researchers access to these next-generation models via the 
American Type Culture Collection. Many of the organoid lines available in this ground­
breaking biorepository are also documented with patient and sequencing information. 
Having such a well-characterized portfolio of cells enables many opportunities for high­
quality experimentation to evaluate ADC performance that was impossible or very hard 
to accomplish in the past. For example, genetically and disease-matched PDOs can be 
used to assess the cytotoxicity of targeted ADCs in vitro or in vivo and be compared 
to matching normal tissue-derived PDOs. As discussed in Section iii, the conjugation of 
different moieties for imaging can be used to visualize where ADCs accumulate naturally in 
the body and whether, once bound to the antigen, they stay on the surface of a cell or are 
internalized.
PDO co-cultures can also be established in vitro to examine critical tumor cell 
interactions with defined aspects of the tumor microenvironment, such as cancer-associated 
fibroblasts[13,14], and possibly also with immune cells in the near future. Such co-cultures 
will enable testing of an ADC on tumor and normal cells at the same time, helping to better 
understand the effects an ADC may have on either cell type or their ability to interact.
The engraftment of human-derived PDO material into a mouse for in vivo studies, as with 
conventional 2D tumor xenograft-based models used for ADC development, necessitates 
the employment of immune-compromised host strains. As such, such in vivo models do 
not allow the study of tumor interactions with a fully intact host immune system. Further 
exploration of the important role played by the host microenvironment in PDO tumor 
development (and potentially ADC interaction) has shown that different implantation sites 
in the same organ can significantly influence in vivo tumor biology. For example, in the 
case of organoids derived from pancreatic ductal adenocarcinoma (the most common form 
of pancreatic cancer), it has been shown that the tumor growth pattern and interaction with 
the microenvironment differ greatly when growing in the parenchyma of the pancreas vs. the 
actual pancreatic duct (where the disease is understood to originate)[15]. No one can argue 
with the relative ease of setting up conventional subcutaneous tumor xenograft models, but 
studies such as these do raise serious questions regarding what aspects of the disease they 
accurately recapitulate.
Taken together, these advances in tumor organoid technology enable more complex, 
rigorous, and informative validation of ADC performance before proceeding to large 
and expensive clinical studies. The broad diversity of human PDO models available will 
massively enrich research efforts and possibilities to validate ADC effects in various disease 
models and thus enable the stratification of the patients who will most likely benefit from 
treatment with a specific ADC molecule.
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ADVANCES IN GENETIC MANIPULATION
A critical aspect of ADC development is to stringently test and understand the specificity 
of binding to the target antigen. This knowledge is ultimately key for successful clinical 
translation and identifying which individual patients are most likely to benefit from 
treatment with the ADC.
The specificity of the antigen is often demonstrated experimentally using different, non­
genetically matched tumor cell lines that differentially express the antigen or a pre-treatment 
block with non-labeled antibody. These are acceptable methods, but recent advances in 
genetic manipulation, namely the widespread adoption of CRISPR (clustered regularly 
interspaced short palindromic repeats), have greatly facilitated the potential adoption of 
significantly higher experimental standards.
An ideal experimental scenario to test antigen specificity in vivo would be to employ 
paired preclinical tumor models, identical in every way except for target antigen 
expression. Tumors plus or minus antigen, developing on contralateral flanks or in matched 
experimental cohorts, would elegantly demonstrate that observed ADC accumulation at a 
tumor is specific and not due to off-target interactions or simple passive accumulation via 
leaky tumor vasculature and the EPR effect.
Traditionally, the only available approach to precisely knock-out the expression of a target 
gene relied upon homologous recombination between a targeting vector and endogenous 
allele[16]. The approach was technical, inefficient, and time consuming to employ and 
was seldom performed in any other context than in the targeting of murine ES cells to 
produce genetically modified mice. The subsequent discovery of RNAi and the ability to 
easily and specifically knock-down gene expression with shRNA[17] or miRNA[18] was 
transformative by rapidly facilitating specific and significantly reduced levels of gene 
expression in practically any eukaryotic cell line of interest. This approach is still valid 
today, however gene knock-down by RNAi is frequently not 100% and so the target antigen 
is still expressed to some extent.
The relatively recent discovery, rapid development, and widespread adoption of CRISPR 
technology has completely revolutionized our ability to precisely modify the genome [19]. 
Among the many documented applications, it is now relatively straightforward and efficient 
to generate such matched tumor model pairs, plus or minus the expression of antigen. 
Briefly, CRISPR introduces precisely targeted double-strand breaks in the genome, which 
are typically imperfectly repaired by non-homologous end joining. This repair process often 
results in the microdeletion of one or more nucleotides at the DSB. Accordingly, bi-allelic 
frame-shifting mutations can be readily introduced into the specific coding sequence of a 
gene of interest, effectively knocking out its expression.
On occasion, knock-out of gene expression is poorly tolerated by the targeted cell, 
significantly affecting cell fitness or causing phenotypic drift, such that the genetically 
paired cell lines are no longer a good match biologically. In those circumstances, inducible 
transgene technology can be employed (e.g., doxycycline inducible expression[20]) to 
limit the amount of time between antigen knock-out and antibody affinity assay. Further, 
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inducible gene expression can introduce or restore the expression of an antigen in a cell line 
that the ADC does not otherwise recognize. For example, the expression of a tumor-specific 
antigen could be readily introduced into a “normal” and non-expressing organoid cell line 
(as mentioned in Section i); implanted cells in non-induced mice will not express the antigen 
and so lack affinity for the ADC, whereas induced mice will become antigen positive and 
show ADC accumulation.
It is significantly easier and faster to manipulate gene expression in cell line-based cancer 
models than in transgenic mice. Therefore, it is exciting that the advances in tumor 
modeling discussed above are to some extent tissue-culture based, as this opens up many 
possibilities for their efficient genetic manipulation and thus thorough and rigorous in vivo 
experimentation.
ADVANCES IN PRECLINICAL IMAGING
Depending on the nature of the conjugated moiety, ADC molecules can be considered 
“theranostic”, a term used to describe a molecule with both therapeutic and diagnostic 
properties. Once a candidate ADC molecule has satisfied stringent in vitro and tissue­
histology performance criteria, preclinical imaging can be used to dynamically measure both 
aspects of this, i.e., to visualize the biodistribution of an ADC molecule in the context of the 
whole body over time and to accurately measure the anticancer effects of ADC treatment. 
Critically, imaging can be used to standardize the timing of ADC administration (e.g., on 
the basis of tumor size) across experimental cohorts of mice and can provide meaningful 
“before and after” ADC treatment measurements of the same tumor in the same individual. 
Collectively, these experimental advantages serve to reduce the number of assumptions 
made in an in vivo study, greatly improving study robustness and reducing animal cohort 
size. Non-invasive imaging is also particularly pertinent in the context of the tumor organoid 
model advances discussed above, as tumors development in orthotopic and deep tissue 
locations are otherwise not visible externally.
Rather than comprehensively review the field of preclinical imaging, we instead mention 
here several key imaging practices that we believe are particularly impactful for current and 
future ADC development.
Approaches to image antibody biodistribution in vivo
ADCs are extremely versatile tumor targeting molecules due to the broad variety of 
functional groups that can be attached to them, whether therapeutic “warheads” used to 
treat cancer or diagnostic ones for tumor imaging. All preclinical imaging modalities 
have relative strengths and weaknesses and so the conjugated imaging moiety should be 
selected based on the nature of the experimental goal. It should also be noted that different 
conjugates will influence the in vivo biodistribution of an ADC and that not all variant ADC 
can be presumed to perform equally.
In the preclinical space, the attachment of a fluorescent moiety (e.g., an Alexa Fluor dye[21]) 
to a candidate ADC can uniquely enable direct visualization and accurate quantitation 
of antibody binding to target cells by microscopy or flow cytometry in vitro. However, 
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fluorescence imaging is in general poorly suited for whole-body in vivo imaging, as visible 
wavelengths of light are poorly tissue penetrant and prone to scatter and absorption from 
overlying tissues[22]. Autofluorescence generated from surrounding gram amounts of non­
labeled tissue can also prove troublesome in the context of attempting to detect a signal 
above background from small, milligram-sized tumors. Intravital microscopy, however, is a 
unique in vivo fluorescence-based imaging approach that allows the researcher to look at the 
accumulation of labeled antibody at the site of tumor development at sub-cellular resolution 
in vivo[23]. No other mainstream in vivo imaging modality can offer this kind of imaging 
scale, but it should be noted that IVM only offers a small field of view with limited depth of 
tissue penetration (0.5 mm) and is only suitable for imaging through an implanted “window” 
at a single location in the body. Fluorescent immunopeptides are also of additional clinical 
interest and are being developed for guided intraoperative imaging purposes, to assist 
surgeons to both locate tumors and set resection margins in theatre[24]. We speculate that 
recent advances in tissue clearing techniques and light sheet microscopy may also enable 
visualization of fluorescent ADC binding at cellular resolution in reconstructed 3D images 
of tissue[25].
Optoacoustic (or photoacoustic) imaging is similar in nature to fluorescence-based 
approaches, but it is better suited for deep tissue imaging. Instead of attaching a fluorophore, 
this approach relies upon the conjugation of a light absorbing or quenching moiety[26,27], 
i.e., the attachment of a molecule with a high molecular extinction co-efficient and low 
quantum yield. Unlike a strong fluorescent label, whereby absorbed excitation energy 
is largely emitted as red-shifted light, a strong photoacoustic label predominantly emits 
absorbed excitation energy as heat. When the excitation light is pulsed in nanosecond bursts, 
the resulting pulses of heat (and associated pulses of thermal tissue expansion) generate 
an ultrasound signal that can be readily detected. Most imaging modalities offer either 
high resolution images with poor image sensitivity (e.g., MRI) or highly sensitive and 
poorly resolved images (e.g., PET). While not yet offering subcellular image resolution 
similar to fluorescence imaging, optoacoustic imaging is a good compromise whole-body 
and clinically translatable imaging modality, offering both reasonable imaging resolution 
and sensitivity at deeper tissue sites.
Arguably the most sensitive and quantifiable way to non-invasively track the biodistribution 
of an ADC candidate molecule throughout the whole body is by PET (positron emission 
tomography). Full-size antibodies have a relatively long serum half-life in vivo and so 
conjugation of the positron emitting isotope Zirconium 89 (t1/2 = 3.3 days) allows follow up 
biodistribution scans for more than a week after administration[28]. Unlike optical signals, 
the gamma rays detected by PET are much less prone to scatter or attenuation from 
overlying tissue. Accordingly, resultant tomographic images are not surface-weighted and 
allow for the detection and discrimination of individual lesions in relatively close proximity, 
irrespective of depth in tissue. Derivative antibody fragments, such as Fabs or diabodies, 
have a significantly shorter serum half-life, often clearing the body within 24 h, and so can 
be adequately imaged by PET with more conventional and shorter-lived radioisotopes, such 
as Fluorine 18[29].
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In the absence of a formal biodistribution study, whole-body PET images of an antibody 
can be used to estimate where in the body the same ADC with a different therapeutic 
radioisotope attached [such as Yttrium 90 (β-emitter) or Actinium 225 (α-emitter)] would 
accumulate in the body. As mentioned above, ADCs with different conjugated moieties 
cannot be assumed to behave in an identical fashion in vivo. Matched pairs of imaging 
and diagnostic radioisotopes [such as Scandium 44 (positron emitter for PET imaging) and 
Scandium 47 (β-emitter for therapy)] are being developed to circumvent such issues, lending 
greater predictive power to the PET scan[30].
Advances in imaging the therapeutic effects of an ADC
In addition to being able to non-invasively track the biodistribution of a candidate ADC 
molecule, preclinical imaging can be equally useful in providing a dynamic and quantifiable 
measure of tumor cell cytotoxicity and therapeutic effect.
The most obvious preclinical modality to mention in this context is bioluminescence 
imaging (BLI). For reasons of relative sensitivity, speed, safety (does not involve ionizing 
radiation), and affordability, this optical imaging modality has been widely adopted by the 
research community[31]. The BLI signal is reliant upon first introducing the expression of 
a luciferase transgene into the tumor model of interest. An expanding list of candidate 
enzymes and substrates suitable for BLI have now been described[32]; however, enzymes 
that rely upon ATP to generate light are the most useful for assessing relative tumor cell 
viability in vivo. A highly relevant feature of these enzymes is that dead cells no longer 
emit light and so the cytotoxic effects of any drug or ADC can be readily assessed following 
treatment. This viability measure is often possible at experimental time-points far earlier 
than when gross anatomic changes to the tumor become evident.
We would also like to draw particular attention to a relatively little used imaging technique 
termed NIS-SPECT. Similar to in vivo bioluminescence imaging, whereby cancer cells are 
first labeled with the expression of a reporter transgene, cells are labeled with Sodium 
Iodide symporter (NIS) expression[33]. Physiologically, NIS expression is predominantly 
limited to the salivary gland, thyroid, stomach, and lactating breast in the mouse and 
transports iodine, an essential component of thyroid hormone biosynthesis. Crucially for 
imaging, NIS also imports the widely available and cheap gamma-emitting radiotracer 
99mpertechnetate, which can be detected by SPECT. In our experience, NIS-SPECT can 
readily detect and individually resolve multiple sub-cubic-millimeter-sized metastatic tumor 
lesions in three-dimensional space (see Figure 2). As background expression of endogenous 
NIS is effectively absent in all organs other than those mentioned above, the signal-to-noise 
ratio is generally excellent and this approach can produce visually striking and accurate 
3D images of tumor development and metastatic spread in vivo. It would be an extremely 
attractive experimental proposition to co-register the 89Zr-labeled ADC biodistribution PET 
image with the NIS-SPECT tumor image, especially in the context of metastatic disease 
models that have been rendered positive or negative for expression of the target antigen (as 
mentioned in Section ii).
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In the immediate future, it is exciting to consider that the confluence of advances in 
cancer modeling, genetic manipulation and preclinical imaging discussed here will be able 
to provide significantly more robust evaluation of candidate ADC performance prior to 
clinical application. This is especially pertinent given the high attrition rate of promising 
candidate molecules as they progressively develop from the laboratory to the clinic. For 
practical reasons, we are not suggesting that these new techniques completely replace 
existing experimental approaches, but they should be considered and applied to some extent 
to rigorously explore key ADC development milestones. Improvements in the methods 
employed to more stringently test and assess the in vivo performance of any candidate drug 
or ADC can only stand to enable more informed “go, no go” decisions earlier in their 
development and ultimately ensure that efforts and resources are focused on those candidate 
molecules identified as most likely to succeed in the clinic and benefit cancer patients.
Acknowledgement
The authors would like to thank Dr. Youngkyu Park and Dr. Dave Tuveson (Figure 1C) and Joseph Merrill and 
Libia Garcia (Figure 2), for kindly providing images used in both figures.
Financial support and sponsorship
This work was supported by grants (NIH/NCI RO1 5R01CA237154–02) - Trotman, NIH/NCI CSHL Cancer Center 
Support Grant 5P30CA45508–33 (Tuveson) - Trotman and Lyons, and by the German Research Foundation (DFG) 
(PL 894/1–1) - Plenker.
REFERENCES
1. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J 
Med2007;357:39–51. [PubMed: 17611206] 
2. Ulaner GA, Hyman DM, Ross DS, et al.Detection of HER2-positive metastases in patients with 
HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT. J Nucl Med2016;57:1523–
8. [PubMed: 27151988] 
3. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. 
Biostatistics2019;20:273–86. [PubMed: 29394327] 
4. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a 
new medicine to market, 2009–2018. JAMA2020;323:844–53. [PubMed: 32125404] 
5. Hingorani AD, Kuan V, Finan C, et al.Improving the odds of drug development success through 
human genomics: modelling study. Sci Rep2019;9:18911. [PubMed: 31827124] 
6. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as 
issues related to its heterogeneity. Adv Drug Deliv Rev2015;91:3–6. [PubMed: 25579058] 
7. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev 
Cancer2006;6:813–23. [PubMed: 16990858] 
8. Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science2019;364:952–
5. [PubMed: 31171691] 
9. Mullenders J, de Jongh E, Brousali A, et al.Mouse and human urothelial cancer organoids: a tool for 
bladder cancer research. Proc Natl Acad Sci U S A2019;116:4567–74. [PubMed: 30787188] 
10. Sachs N, de Ligt J, Kopper O, et al.A living biobank of breast cancer organoids captures disease 
heterogeneity. Cell2018;172:373–386.e10. [PubMed: 29224780] 
11. Tiriac H, Belleau P, Engle DD, et al.Organoid profiling identifies common responders to 
chemotherapy in pancreatic cancer. Cancer Discov2018;8:1112–29. [PubMed: 29853643] 
Lyons et al. Page 9













12. HCMI. Available from: https://www.atcc.org/Products/Cells%20and%20Microorganisms/
HCMI.aspx [Last accessed on 7 Jul 2021].
13. Sahai E, Astsaturov I, Cukierman E, et al.A framework for advancing our understanding of 
cancer-associated fibroblasts. Nat Rev Cancer2020;20:174–86. [PubMed: 31980749] 
14. Biffi G, Oni TE, Spielman B, et al.IL1-induced JAK/STAT signaling is antagonized by TGFβ to 
shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov2019;9:282–301. 
[PubMed: 30366930] 
15. Miyabayashi K, Baker LA, Deschênes A, et al.Intraductal transplantation models of human 
pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes. Cancer 
Discov2020;10:1566–89. [PubMed: 32703770] 
16. Capecchi MR. Altering the genome by homologous recombination. Science1989;244:1288–92. 
[PubMed: 2660260] 
17. Sandy P, Ventura A, Jacks T. Mammalian RNAi: a practical guide. Biotechniques2005;39:215–24. 
[PubMed: 16116795] 
18. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for 
single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U 
S A2005;102:13212–7. [PubMed: 16141338] 
19. Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun2018;9:1911. 
[PubMed: 29765029] 
20. Loew R, Heinz N, Hampf M, Bujard H, Gossen M. Improved Tet-responsive promoters with 
minimized background expression. BMC Biotechnol2010;10:81. [PubMed: 21106052] 
21. Koga S, Oshima Y, Honkura N, et al.In vivo subcellular imaging of tumors in mouse models 
using a fluorophore-conjugated anticarcinoembryonic antigen antibody in two-photon excitation 
microscopy. Cancer Sci2014;105:1299–306. [PubMed: 25117702] 
22. Rice BW, Contag CH. The importance of being red. Nat Biotechnol2009;27:624–5. [PubMed: 
19587667] 
23. Li R, Attari A, Prytyskach M, Garlin MA, Weissleder R, Miller MA. Single-cell intravital 
microscopy of trastuzumab quantifies heterogeneous in vivo kinetics. Cytometry A2020;97:528–
39. [PubMed: 31423731] 
24. Voskuil FJ, de Jongh SJ, Hooghiemstra WTR, et al.Fluorescence-guided imaging for resection 
margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative 
dose-escalation study. Theranostics2020;10:3994–4005. [PubMed: 32226534] 
25. Renier N, Wu Z, Simon DJ, Yang J, Ariel P, Tessier-Lavigne M. iDISCO: a simple, rapid method 
to immunolabel large tissue samples for volume imaging. Cell2014;159:896–910. [PubMed: 
25417164] 
26. Weber J, Beard PC, Bohndiek SE. Contrast agents for molecular photoacoustic imaging.Nat 
Methods2016;13:639–50. [PubMed: 27467727] 
27. Zhang C, Zhang Y, Hong K, Zhu S, Wan J. Photoacoustic and fluorescence imaging of 
cutaneous squamous cell carcinoma in living subjects using a probe targeting integrin αvβ6. Sci 
Rep2017;7:42442. [PubMed: 28181579] 
28. Yoon JK, Park BN, Ryu EK, An YS, Lee SJ. Current perspectives on 89Zr-PET imaging. Int J Mol 
Sci2020;21:E4309. [PubMed: 32560337] 
29. Wu AM. Engineered antibodies for molecular imaging of cancer. Methods2014;65:139–47. 
[PubMed: 24091005] 
30. Carter KP, Deblonde GJ, Lohrey TD, et al.Developing scandium and yttrium coordination 
chemistry to advance theranostic radiopharmaceuticals. Commun Chem2020:3.
31. Lyons SK, Patrick PS, Brindle KM. Imaging mouse cancer models in vivo using reporter 
transgenes. Cold Spring Harb Protoc2013;2013:685–99. [PubMed: 23906907] 
32. Yao Z, Zhang BS, Prescher JA. Advances in bioluminescence imaging: new probes from old 
recipes. Curr Opin Chem Biol2018;45:148–56. [PubMed: 29879594] 
33. Vandergaast R, Khongwichit S, Jiang H, et al.Enhanced noninvasive imaging of oncology models 
using the NIS reporter gene and bioluminescence imaging. Cancer Gene Ther2020;27:179–88. 
[PubMed: 30674994] 
Lyons et al. Page 10














An example of pancreatic tumor organoids growing in culture and in vivo. (A) A brightfield 
microscopy image of organoids growing in structured 3D spheres in Matrigel in vitro. 
Organoids can be efficiently generated from a wide range of epithelial tissues and, as 
they are genetically stable over an extended time in culture, are amenable to genetic 
manipulation. (B) A schematic of how an organoid’s sensitivity to a therapeutic can 
be presented. Organoid cell viability can be measured in a high-throughput manner by 
standard assay techniques [e.g., CellTiter-Glo (Promega)] and plotted against drug or ADC 
concentration. The therapeutic responses of normal, tumor, and metastatic organoids derived 
from the same patient, organoids from different patients, or genetically modified variant 
organoids can be readily compared. (C) Two serial sections of a pancreatic tumor developed 
in vivo following orthotopic implantation of tumor organoid cells. The top panel is an 
H&E stain, highlighting regions of tumor cells in deep purple. The bottom panel is a 
Masson’s trichrome stain, which stains collagen blue. These organoid tumors develop a 
dense stroma composed of connective tissue and fibroblasts when grown orthotopically in 
vivo, recapitulating key clinical characteristics.
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An example of a metastatic prostate cancer model with the tumors labeled with: firefly 
luciferase (A); and NIS expression (B). The BLI image (A) takes less than 1 min to 
acquire, and, as only the tumor cells emit light, it clearly shows widespread dissemination 
of metastases throughout the body, most clearly in the abdomen and leg. The optical signal 
is absorbed and scattered by overlying tissue, thus it is not possible to resolve individual 
lesions by this imaging method. A NIS-SPECT image of the same mouse (B) shows the 
same tumor burden, but now in 3D. Metastases are clearly present and prevalent in the liver 
and bone (spine, skull, and femur) of this mouse. Some normal organs in the body also 
express NIS and so also show up on the scan. SG: Salivary gland/thyroid; ST: stomach; 
BL: bladder (excretion route of 99mTcO4 probe). (C) Images of a femur from a different 
mouse with a prostate tumor metastasis. The top panel is a CT image only and shows clear 
evidence of bone degradation. When the NIS-SPECT image is co-registered, it is clear that 
an osteolytic lesion is growing in this part of the bone.
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